Greener purification at large-scale

An oligonucleotide case study

Resembling a new era of innovative drug development, the interest of the biopharma industry in the oligonucleotide markets has grown significantly in the past five years. Originally targeting rare diseases, the use of oligonucleotide-based drugs is now moving towards more common therapeutic areas with the need to address larger patient populations. In 2021, the US Food and Drug Administration (FDA) approved the first-in-class siRNA to lower cholesterol – a drug with a multi-ton potential to treat millions of patients per year. Moving forward, the demand for oligonucleotide batch size is likely to increase as well as the need for large-scale manufacturing capacity to support this growth.

Download case study

By completing this form, the requested document will be sent directly to your email.

Oligo case study cover